Antimicrobial copper-alloy touch surfaces follows: The following claims are now legally permitted when marketing EPA-registered antimicrobial copper alloys in the U.S.: The registrations state that “antimicrobial copper alloys may be used in hospitals, other healthcare facilities, and various public, commercial and residential buildings.” The EPA copper alloy registrations were granted “with public health claims,” meaning that they permit manufacturers of copper-based products sold in the U.S. to claim on their labels the ability of copper, brass, and bronze to kill harmful, potentially deadly bacteria. As a condition of registration established by EPA, the Copper Development Association (CDA) in the U.S. is responsible for the
Antimicrobial copper-alloy touch surfaces in rooms with copper touch surfaces were significantly lower than in rooms without copper surfaces. "Staphylococci" were the most predominant microorganism isolated and copper was effective in reducing the "Staphylococci" microbial burden. Further studies regarding the clinical implications of copper's intrinsic ability to reduce microbial burdens in hospitals are being planned. Researchers from the Kitasato University School of Medicine conducted antimicrobial studies of "S. aureus", "E. coli", and "P. aeruginosa" on various Japanese copper alloy coins and on copper alloy plates. The microbes were strains from hospital environments. Copper and its nickel-silver, cupronickel, and brass alloys were found to kill